The impact of mechanical ventilation on the moxifloxacin treatment of experimental pneumonia caused by Streptococcus pneumoniae

Critical Care Medicine

Volumn 33, Issue 5, 2005, Pages 1029-1035

  Charles, Pierre Emmanuel ^a   Etienne, Manuel ^a   Croisier, Delphine ^a   Piroth, Lionel ^a   Lequeu, Catherine ^a   Pugin, Jerome ^b   Portier, Henri ^a   Chavanet, Pascal ^a  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Animal model; Community acquired pneumonia; Mechanical ventilation; Moxifloxacin; Pharmacokinetics; Streptococcus pneumoniae; Ventilator associated pneumonia; Ventilator induced lung injury

Indexed keywords

MOXIFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL VENTILATION; BACTEREMIA; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RABBIT; SPLEEN; STREPTOCOCCUS PNEUMONIAE; SURVIVAL RATE; TISSUE CULTURE;

ANIMALS; AREA UNDER CURVE; AZA COMPOUNDS; COMMUNITY-ACQUIRED INFECTIONS; DISEASE MODELS, ANIMAL; HALF-LIFE; MALE; PNEUMOCOCCAL INFECTIONS; QUINOLINES; RABBITS; RESPIRATION, ARTIFICIAL;

EID: 18344386693     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000163404.35338.72     Document Type: Article

References (38)

1. Moine P, Vercken J, Chevret S, et al: Severe community-acquired pneumococcal pneumonia. The French study group of community-acquired pneumonia in ICU. Scand J Infect Dis 1995; 27:201-206
2. Watanakunakorn C, Bailey T: Adult bacteremic pneumococcal pneumonia in a community teaching hospital, 1992-1996. Arch Intern Med 1997; 157:1965-1971
3. Georges H, Leroy O, Vandenbussche C, et al: Epidemiological features and prognosis of severe community-acquired pneumococcal pneumonia. Intensive Care Med 1999; 25:198-206
4. Hook E, Horton C, Schaberg D: Failure of intensive care unit support to influence mortality from pneumococcal bacteremia. JAMA 1983; 249:1055-1057
5. Torres A, Serra-Battles J, Ferrer A, et al: Severe community-acquired pneumonia. Epidemiology and prognosis factors. Am Rev Respir Dis 1991; 144:312-318
6. Leroy O, Georges H, Beuscart C, et al: Severe community-acquired pneumonia in ICU: Prospective validation of a prognostic score. Intensive Care Med 1996; 22:1307-1314
7. Sirvent JM, Torres A, Vidaur L, et al: Tracheal colonisation within 24 h of intubation in patients with head trauma: Risk factor for developing early-onset ventilator-associated pneumonia. Intensive Care Med 2000; 26:1369-1372
8. Charles PE, Piroth L, Desbiolles N, et al: New model of ventilator-associated pneumonia in immunocompetent rabbits. Crit Care Med 2002; 30:2278-2283
9. Marquette CH, Wermert D, Wallet F, et al: Characterization of an animal model of ventilator-acquired pneumonia. Chest 1999; 115:200-209
10. Nahum A, Hoyt J, Schmitz L, et al: Effect of mechanical ventilation strategy on dissemination of intratracheally instilled Escherichia coli in dogs. Crit Care Med 1997; 25:1733-1743
11. Verbrugge SJC, Sorm V, Vantven A, et al: Lung overinflation without positive endexpiratory pressure promotes bacteremia after experimental Klebsiella pneumonias inoculation. Intensive Care Med 1998; 24:172-177
12. Murphy DB, Cregg N, Tremblay LN, et al: Adverse ventilatory strategy causes pulmonary-to-systemic translocation of endotoxin. Am J Respir Crit Care Med 2000; 162:27-33
13. Schortgen F, Bouadma L, Joly-Grillou ML, et al: Infectious and inflammatory dissemination are affected by ventilation strategy in rats with unilateral pneumonia. Intensive Care Med 2004; 30:693-701
14. Van Dalen R, Vree TB: Pharmacokinetics of antibiotics in critically ill patients. Intensive Care Med 1990; 16:S235-S238
15. Croisier D, Etienne M, Bergoin E, et al: Value of the mutant selection window in the pharmacodynamics of mutants: Application to levofloxacin and moxifloxacin treatment on experimental pneumococcal pneumonia in human-like treated rabbits. Antimicrob Agents Chemother 2004; 48:1699-1707
16. Guide for the Care and Use of Laboratory Animals (No. 92-23). Bethesda, MD, National Institutes of Health, 1985
17. Piroth L, Martin L, Coulon A, et al: Development of a new experimental model of penicillin-resistant Streptococcus pneumoniae pneumonia and amoxicillin treatment by reproducing human pharmacokinetics. Antimicrob Agents Chemother 1999; 43:2484-2492
18. Piroth L, Desbiolles N, Mateo-Ponce V, et al: HMR 3647 human-like treatment of experimental pneumonia due to penicillin-resistant and erythromycin-resistant Streptococcus pneumoniae. J Antimicrob Chemother 2001; 47:33-42
19. Stass H, Kubitza D: Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 1999; 43SB:83-90
20. Johanson WG Jr, Higushi JH, Woods DE, et al: Dissemination of Pseudomonas aeruginosa during lung infection in hamsters. Role of oxygen-induced lung injury. Am Rev Respir Dis 1985; 132:358-361
21. Warner AE, Molina RM, Brain JD: Uptake of bloodborne bacteria by pulmonary intravascular macrophages and consequent inflammatory response in sheep. Am Rev Respir Dis 1987; 136:683-690
22. Yamaoka K, Nakagawa T, Uno T: Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978; 6:162-175
23. Soman A, Honeybourne D, Andrews J, et al: Concentrations of moxifloxacin in serum and pulmonary compartments following a single oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 1999; 44:835-838
24. Savel RH, Yao EC, Gropper MA: Protective effects of low tidal volume ventilation in a rabbit model of Pseudomonas aeruginosa-induced acute lung injury. Crit Care Med 2001; 29:392-398
25. Bregeon F, Roch A, Delpierre S, et al: Conventional mechanical ventilation of healthy lungs induced pro-inflammatory cytokine gene transcription. Respir Physiol Neurobiol 2002; 132:191-203
26. Finch R, Schurmann D, Collins O, et al: Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-Amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002; 46:1746-1754
27. Bartlett JG, Dowell SF, Mandell LA, et al: Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000; 31:347-382
28. Martin C, Lambert D, Bruguerolle B, et al: Ofloxacin pharmacokinetics in mechanically ventilated patients. Antimicrob Agents Chemother 1991; 35:1582-1585
29. Dreyfuss D, Saumon G: Ventilation-induced lung injury. Lessons from experimental studies. Am J Respir Crit Care Med 1998; 157:294-323
30. Lamer C, De Beco V, Soler P, et al: Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993; 37:281-286
31. Goldstein I, Wallet F, Robert J, et al: Lung tissue concentrations of nebulized amikacin during mechanical ventilation in piglets with healthy lungs. Am J Respir Crit Care Med 2002; 165:171-175
32. Elman M, Goldstein I, Marquette C, et al: Influence of lung aeration on pulmonary concentrations of nebulized and intravenous amikacin in ventilated piglets with severe bronchopneumonia. Anesthesiology 2002; 97:199-206
33. Leone M, Albanese J, Sampol-Manos E, et al: Moxifloxacin penetration in bronchial secretions of mechanically ventilated patients with pneumonia. Antimicrob Agents Chemother 2004; 48:638-640
34. Mimoz O, Jacolot A, Padoin C, et al: Influence of experimental rat model of multiple organ dysfunction on cefepime and amikacin pharmacokinetics. Antimicrob Agents Chemother 1996; 40:819-821
35. Boselli E, Breihl D, Cannesson M, et al: Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia. Intensive Care Med 2004; 30:976-979
36. Boselli E, Breihl D, Duflo F, et al: Steadystate plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia. Crit Care Med 2003; 31:2102-2106
37. Nix D, Goodwin S, Peloquin C, et al: Antibiotic tissue penetration and its relevance: Models of tissue penetration and their meaning. Antimicrob Agents Chemother 1991; 35:1947-1952
38. Pugin J: Molecular mechanisms of lung cell activation induced by cyclic stretch. Crit Care Med 2003; 31:8200-8206